The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Frontken Corporation Bhd
KLSE:FRONTKN
|
MY |
|
Supermax Corporation Bhd
OTC:SPMXF
|
MY |
|
I
|
Imperial Pacific Ltd
ASX:IPC
|
AU |
|
G
|
GreenBee Inc
TSE:3913
|
JP |
|
A
|
Alkane Resources Ltd
XMUN:AK7
|
AU |
|
Nitto Denko Corp
OTC:NDEKY
|
JP |
|
Elvictor Group Inc
OTC:ELVG
|
GR |
|
Dupont De Nemours Inc
NYSE:DD
|
US |
|
T
|
Techtronic Industries Co Ltd
XMUN:TIB1
|
HK |
|
Immuron Ltd
ASX:IMC
|
AU |
|
Revenio Group Oyj
F:R0V
|
FI |
|
V
|
Valmet Corp
XMUN:2VO
|
FI |
|
G
|
Glostrext Bhd
KLSE:GLXT
|
MY |
|
H & M Hennes & Mauritz AB
STO:HM B
|
SE |
|
Y
|
Yellow Cake PLC
OTC:YLLXF
|
JE |
|
Envipco Holding NV
F:E1P0
|
NL |
|
A
|
Alibaba Group Holding Ltd
SWB:AHLA
|
HK |
|
Thule Group AB
F:TU0
|
SE |
|
C
|
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
|
AU |
|
A
|
African Pioneer PLC
F:9TI
|
IM |
|
Minera IRL Ltd
OTC:MRLLF
|
PE |
|
T
|
Telefonaktiebolaget LM Ericsson
F:ERCG
|
SE |
|
N
|
NOVONIX Ltd
NASDAQ:NVX
|
AU |
|
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
|
ES |
Frontken Corporation Bhd (FRONTKN)’s 12-month stock price forecast through October 2027 has a consensus target of 5.82 MYR, implying 18% upside. The forecast is based on price targets from 13 Wall Street analysts.
Past growth per year Not enough data
Average annual growth cannot be calculated for these periods.
Explore analyst estimates, growth and forecast ranges.
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
According to Wall Street analysts, the average 1-year price target for FRONTKN is 5.82 MYR with a low forecast of 5.15 MYR and a high forecast of 6.15 MYR.
Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 3 years is 19%.
Over the last 13 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 3 years is 18%.
Over the last 13 years, the compound annual growth rate for Operating Income has been 31%. The projected CAGR for the next 3 years is 20%.
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 39%. The projected CAGR for the next 3 years is 24%.
Over the last 13 years, the compound annual growth rate for Net Income has been 33%. The projected CAGR for the next 3 years is 24%.
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
AI-generated answers can contain mistakes, outdated facts, or incomplete information. Always verify important details before making decisions.
The AI Assistant is designed for research and education. It does not provide personalized investment, legal, or tax advice.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more